riluzole has been researched along with Feeding and Eating Disorders in 1 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Feeding and Eating Disorders: A group of disorders characterized by physiological and psychological disturbances in appetite or food intake.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sasso, DA | 1 |
| Kalanithi, PS | 1 |
| Trueblood, KV | 1 |
| Pittenger, C | 1 |
| Kelmendi, B | 1 |
| Wayslink, S | 1 |
| Malison, RT | 1 |
| Krystal, JH | 1 |
| Coric, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole: An Antiglutamatergic Agent[NCT00251303] | Phase 2 | 78 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CY-BOCS is a 0-40 point scale of obsessive-compulsive symptom severity, higher number indicates more severe obsessive-compulsive symptoms. Comparison of 12 weeks scores for placebo and riluzole groups. (NCT00251303)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Riluzole | 21.72 |
| Placebo | 23.30 |
(NCT00251303)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Riluzole | 3 |
| Placebo | 4 |
1 other study available for riluzole and Feeding and Eating Disorders
| Article | Year |
|---|---|
Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Feeding and Eating Disorders; Female; | 2006 |